Health-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy

Jake Thompson; Julia Lai‐Kwon; Rachael L. Morton; Alexander Guminski; Maria Gonzalez; Victoria Atkinson; Shahneen Sandhu; Michael P. Brown; Alexander M. Menzies; Grant A. McArthur; Serigne Lo; Georgina V. Long; Iris Bartula

doi:10.2217/imt-2022-0262

Abstract

1 min read

Aims: To describe the health-related quality of life (HRQoL) of melanoma brain metastasis (MBM) patients throughout the first 18 weeks of ipilimumab–nivolumab or nivolumab treatment. Materials & methods: HRQoL data (European Organisation for Research and Treatment of Cancer's Core Quality of Life Questionnaire, additional Brain Neoplasm Module, and EuroQol 5-Dimension 5-Level Questionnaire) were collected as a secondary outcome of the Anti-PD1 Brain Collaboration phase II trial. Mixed linear modeling assessed changes over time, whereas the Kaplan–Meier method was used to determine median time to first deterioration. Results: Asymptomatic MBM patients treated with ipilimumab–nivolumab (n = 33) or nivolumab (n = 24) maintained baseline HRQoL. MBM patients with symptoms or leptomeningeal/progressive disease treated with nivolumab (n = 14) reported a statistically significant trend toward improvement. Conclusion: MBM patients treated with either ipilimumab–nivolumab or nivolumab did not report a significant deterioration in HRQoL within 18 weeks of treatment initiation. Clinical trial registration: NCT02374242 (ClinicalTrials.gov)

Related publications

Article2016

A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study).

Georgina V. Long, Victoria Atkinson, Alexander M. Menzies, Alexander Guminski, Shahneen Sandhu, Michael P. Brown, Tracy T.Y.E. Liaw, Maria Gonzalez, Jill Davison, Elizabeth Paton, Richard A. Scolyer, Louise Emmett, Grant A. McArthur

Article2017

A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).

Georgina V. Long, Victoria Atkinson, Alexander M. Menzies, Serigne Lo, Alexander Guminski, Michael P. Brown, M. M. González, Katrina Diamante, Shahneen Sandhu, Richard A. Scolyer, Louise Emmett, Grant A. McArthur

Article2021

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Peter K. H. Lau, Breon Feran, Lorey Smith, Arian Lasocki, Ramyar Molania, Kortnye Smith, Alison M. Weppler, Christopher Angel, Damien Kee, Prachi Bhave, Belinda Lee, Richard J. Young, Amir Iravani, Hanxian Aw Yeang, Ismael A. Vergara, David L. Kok, Kate Drummond, Paul J. Neeson, Karen E. Sheppard, Anthony T. Papenfuss, Benjamin Solomon, Shahneen Sandhu,

Article2021

Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

Torben Plesner, Meletios A Dimopoulos, Albert Oriol, Jesús F. San Miguel, Nizar J. Bahlis, Neil Rabin, Kenshi Suzuki, Sung‐Soo Yoon, Dina Ben‐Yehuda, Gordon Cook, Hartmut Goldschmidt, Sebastian Grosicki, Xiang Qin, John Fastenau, Wendy Garvin, Robin Carson, Thomas Renaud, Katharine S. Gries

Article2022

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stéphane Dalle, Nicolás Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Muñoz‐Couselo, Michael P. Brown, ,